The Cytokine Storm Company

Recent News

June 14, 2021
Humanigen Initiates Submission for Lenzilumab Marketing Authorization in COVID-19, to the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA)

May 28, 2021
Humanigen Submits Application to FDA for Emergency Use Authorization for Lenzilumab in COVID-19

Aim of first-ever CMML study – to improve survival

About Us

We are a clinical stage biopharmaceutical company, developing our immunology and immuno-oncology portfolio of monoclonal antibodies. We are focusing our efforts on the development of our lead product candidate, lenzilumab, our proprietary Humaneered® (“Humaneered”) anti-human granulocyte-macrophage colony-stimulating factor (“GM-CSF”) monoclonal antibody.


"The more original a discovery the more obvious it seems afterwards."

Arthur Koestler